PFE - ViiV HIV doublet therapy on par with triplet in previously untreated adults

Three year data from the Phase 3 GEMINI 1 and GEMINI 2 studies evaluating ViiV Healthcare's two-drug regimen of dolutegravir and lamivudine (branded as Dovato) showed it to be non-inferior (no worse than) to the three-drug regimen of dolutegravir plus two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in treatment-naïve adults with HIV-1. The results were presented at HIV Glasgow.On the treatment resistance front, only 1.7% (n=12/716) of patients experienced confirmed virologic withdrawal compared to 1.3% (n=9/717) in the dolutegravir + TDF/FTC group. None developed treatment-emergent resistance mutations.The FDA approved Dovato in April 2019 for treatment-naïve adults with HIV-1.ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (GSK) (+1%), Pfizer (PFE) (+1%) and Shionogi (SGIOY).

For further details see:

ViiV HIV doublet therapy on par with triplet in previously untreated adults